Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01355952 · ClinicalTrials.gov registry record · NA
An Open-Label Pilot Trial of Alpha Lipoic Acid (ALA) for Weight Loss in Schizophrenia
A NA study, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 17
- Enrollment target
NCT01355952 is a NA study that has completed, run by Yale University. The registered enrollment target is 17 participants.
The verdict
NCT01355952, a NA study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 17 participants
- Enrollment target
Study Summary
The aim of this study is to collect pilot data to compare the effectiveness of treatment with Alpha Lipoic Acid (ALA) for reduction in body weight in 40 obese outpatients with schizophrenia or schizoaffective disorder in an open-label pilot trial. The investigators also plan to test the feasibility of utilizing ALA as a weight loss agent for obese outpatients with schizophrenia or schizoaffective disorder in terms of tolerability, schizophrenia symptoms, cognition and side effects. We have run a total of 12 non-diabetic participants and are now recruiting diabetic patients in hopes of comparing the two groups.
Interventions
- DIETARY_SUPPLEMENT Alpha Lipoic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2011-05 |
| Est. Completion | 2012-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01355952
The ClinicalTrials.gov registry entry for NCT01355952 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Alpha Lipoic Acid is the first listed.
NCT01355952 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01355952 about?
NCT01355952 is a clinical study titled "An Open-Label Pilot Trial of Alpha Lipoic Acid (ALA) for Weight Loss in Schizophrenia". The aim of this study is to collect pilot data to compare the effectiveness of treatment with Alpha Lipoic Acid (ALA) for reduction in body weight in 40 obese outpatients with schizophrenia or schizoaffective disorder in an open-label pilot trial. The investigators also plan to test the feasibility ...
What is the current status of trial NCT01355952?
This trial is currently completed. It is a NA study. The enrollment target is 17 participants. The study started on 2011-05. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01355952?
The interventions under investigation include: Alpha Lipoic Acid (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01355952?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.